Osteogenic Potential of Human Umbilical Cord Mesenchymal Stem Cells on Coralline Hydroxyapatite/Calcium Carbonate Microparticles

被引:17
作者
Day, A. G. E. [1 ]
Francis, W. R. [1 ]
Fu, K. [2 ]
Pieper, I. L. [1 ]
Guy, O. [3 ]
Xia, Z. [1 ]
机构
[1] Swansea Univ, Med Sch, Inst Life Sci, Swansea SA2 8PP, W Glam, Wales
[2] Hainan Med Coll, Affiliated Hosp 1, Dept Orthopaed Surg, Haikou, Hainan, Peoples R China
[3] Swansea Univ, Coll Engn, Swansea SA2 8PP, W Glam, Wales
基金
中国国家自然科学基金;
关键词
BONE-GRAFT SUBSTITUTE; IN-VIVO; GENE-EXPRESSION; STROMAL CELLS; DIFFERENTIATION; MODEL;
D O I
10.1155/2018/4258613
中图分类号
Q813 [细胞工程];
学科分类号
100113 [医学细胞生物学];
摘要
Coralline hydroxyapatite/calcium carbonate (CHACC) is a biodegradable and osteoconductive bone graft material with promising clinical performance. CHACC has been shown to support proliferation and osteogenic differentiation of human bone marrow mesenchymal stem cells (MSCs) in vitro and demonstrated to work as a functional scaffold for bone formation in vivo. Umbilical cord matrix is a more accessible and abundant tissue source of MSCs, but its osteogenic capacity in comparison to human bone marrow when cultured on CHACC has not yet been demonstrated. In this study, we assessed the osteogenic differentiation capacity of human MSCs, isolated from bone marrow and umbilical cord matrix and characterised by flow cytometry, when cultured on 200-300 mu m CHACC granules. The 3D cultures were characterised by brightfield and scanning electron microscopy (SEM). Osteogenic potential was assessed by immunocytochemistry and qPCR for key markers of bone differentiation (alkaline phosphatase, runx2, type I collagen, and osteocalcin). By day 1, the MSCs had enveloped the surface of the CHACC granules to form organoids, and by day 7, cells had proliferated to bridge nearby organoids. Extracellular matrix deposition and osteogenic differentiation were demonstrated by MSCs from both tissue sources at day 21. However, MSCs from bone marrow demonstrated superior osteogenic differentiation capability compared to those from umbilical cord matrix. In conclusion, it is possible to culture and induce osteogenic differentiation of umbilical cord matrix MSCs on CHACC. Further research is required to optimise the osteogenicity of umbilical cord matrix MSCs to release their full potential as a readily available, accessible, and abundant tissue source for bone tissue engineering.
引用
收藏
页数:9
相关论文
共 33 条
[1]
Publishing flow cytometry data [J].
Alvarez, D. F. ;
Helm, K. ;
DeGregori, J. ;
Roederer, M. ;
Majka, S. .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2010, 298 (02) :L127-L130
[2]
Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments [J].
Astashkina, Anna ;
Grainger, David W. .
ADVANCED DRUG DELIVERY REVIEWS, 2014, 69 :1-18
[3]
Concise review: Human umbilical cord stroma with regard to the source of fetus-derived stem cells [J].
Can, Alp ;
Karahuseyinoglu, Sercin .
STEM CELLS, 2007, 25 (11) :2886-2895
[4]
Angiogenic and osteogenic regeneration in rats via calcium phosphate scaffold and endothelial cell co-culture with human bone marrow mesenchymal stem cells (MSCs), human umbilical cord MSCs, human induced pluripotent stem cell-derived MSCs and human embryonic stem cell-derived MSCs [J].
Chen, Wenchuan ;
Liu, Xian ;
Chen, Qianmin ;
Bao, Chongyun ;
Zhao, Liang ;
Zhu, Zhimin ;
Xu, Hockin H. K. .
JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, 2018, 12 (01) :191-203
[5]
COSTANTINO PD, 1994, OTOLARYNG CLIN N AM, V27, P1037
[6]
Human umbilical cord mesenchymal stem cells: Osteogenesis in vivo as seed cells for bone tissue engineering [J].
Diao, Yinze ;
Ma, Qingjun ;
Cui, Fuzhai ;
Zhong, Yanfeng .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2009, 91A (01) :123-131
[7]
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[8]
A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice [J].
Eliopoulos, N ;
Al-Khaldi, A ;
Crosato, M ;
Lachapelle, K ;
Galipeau, J .
GENE THERAPY, 2003, 10 (06) :478-489
[9]
BONE-BANKING [J].
FRIEDLAENDER, GE .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1982, 64 (02) :307-311
[10]
Fu K, 2008, CALCIFIED TISSUE INT, V83, P20